PEN Stock: Price, Earnings History and SEC Filings
Penumbra, Inc. (PEN) last traded at $318.95, down 0.94% on the latest session and up 0.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.88 against an analyst estimate of $1.15, a miss of 23.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PEN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $0.88 | $1.15 | -23.48% |
| Mar 2026 | May 6, 2026 | $0.82 | $1.11 | -26.13% |
| Dec 2025 | Feb 25, 2026 | $1.18 | $1.12 | +5.36% |
PEN beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
How PEN reacts to earnings
Across its last 8 earnings releases, PEN moved 6.2% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -0.94% |
| 2026-07-30 | After close | +0.43% |
| 2026-05-06 | After close | +0.14% |
| 2026-02-25 | Before open | -0.27% |
| 2026-01-15 | Before open | +11.82% |
| 2025-11-05 | After close | +17.32% |
| 2025-07-29 | After close | +11.91% |
| 2025-04-23 | After close | +6.99% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PEN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.4B | $178M | $175M | 12.7% | $4.52 |
| 2024 | $1.2B | $14M | $147M | 1.2% | $0.36 |
| 2023 | $1.1B | $91M | $82M | 8.6% | $2.32 |
| 2022 | $847M | -$2M | -$75M | -0.2% | $-0.05 |
| 2021 | $748M | $5M | -$12M | 0.7% | $0.14 |
| 2020 | $560M | -$16M | -$58M | -2.8% | $-0.44 |
| 2019 | $547M | $48M | $5M | 8.9% | $1.34 |
| 2018 | $445M | $7M | $19M | 1.5% | $0.18 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PEN
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 22, 2026Shareholder vote
- 8-K · May 7, 2026Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 29, 2026
- 10-K · Feb 25, 2026
Insider filing activity
PEN insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PEN news
- Penumbra (PEN) Stock Faces Q3 Earnings Valuation ScrutinyOct 31, 2026 · finance.yahoo.com
- Penumbra: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
- Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- BSX Q3 Earnings Call Flags Growth Challenges Through 2027Oct 29, 2026 · finance.yahoo.com
- Boston Scientific Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- Boston Scientific: 3 Key Takeaways for Long-Term InvestorsOct 29, 2026 · fool.com
- Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)Oct 20, 2026 · finance.yahoo.com
About Penumbra, Inc.
Penumbra, Inc. (PEN) is a US-listed public company on NYSE. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.